CML—What to do About Imatinib Resistance; When to Consider Transplant: Part II: Interview With Dr. Jane Apperley
Dr. Jane Apperley: Part II: CML—What to do About Imatinib Resistance; When to Consider Transplant
Interview by L Scott Zoeller
20101023
2010 Nov 23
OncologySTAT Editorial Team
CML—What to do About Imatinib Resistance; When to Consider Transplant: Part II: Interview With Dr. Jane Apperley
OncologySTAT Editorial Team. 2010 Nov 23, Interview by L Scott Zoeller
Abstract
Dr. Jane Apperley is Professor of Hemato-oncology, Imperial College London. In part I of this interview, Dr. Apperley discusses treatment options for patients with newly diagnosed CML.Part II: Imatinib ResistanceOncologySTAT: What is the recommended approach for second-line therapy in patients with imatinib-resistant disease?Dr. Apperley: Of course, one would want to absolutely identify that the patient is resistant. We from time to time see patients who are doing fine on imatinib and then suddenly...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
